Director/PDMR Shareholding

RNS Number : 5416Z

Hikma Pharmaceuticals Plc

16 March 2012

 



Hikma Pharmaceuticals PLC - LTIP Awards

LONDON, 16 March 2012: Hikma Pharmaceuticals PLC (LSE: HIK) (DIFX: HIK) announces that the Remuneration Committee has made the following nil-cost awards under the Hikma Pharmaceuticals PLC 2005 Long-Term Incentive Plan (the "LTIP") to Persons Discharging Managerial Responsibility ("PDMR") of the Company.

Awards under the LTIP were made on 16 March 2012 at a price of £7.40p per ordinary share as follows:-

Name of PDMR	Number of LTIP Shares
Bassam Kanaan	46,300
Michael Raya	43,800
Khalid Nabilsi	26,000
Riad Mishlawi	20,700
Henry Knowles	23,700
Susan Ringdal	22,200
Jason Grenfell-Gardener	20,900

The shares subject to the LTIP awards will only be released to the participants in three years time, subject to their continued employment and the satisfaction of the comparative Total Shareholder Return ("TSR"), sales growth, earnings per share ("EPS") growth and return on invested capital ("ROIC") performance targets. Half of the award is subject to TSR against the Comparator Group and requires at least upper quartile performance to vest in full. The remaining half is split equally between the financial targets and requires sales growth of 13%, EPS growth of 20% and ROIC of 12% to vest in full. Each target is measured individually and is independent of the other targets.

- ENDS -

Enquiries:

Hikma Pharmaceuticals PLC         

Henry Knowles                                                [phone]

Company Secretary

Susan Ringdal                                                 [phone]

Investor Relations Director

About Hikma

Hikma Pharmaceuticals PLC is a fast growing multinational pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non‐branded generic and in‐licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based principally in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. In 2011, Hikma achieved revenue of $918.0 million and profit attributable to shareholders of $80.1 million.

 

END

 

 

RDSBUGDXGDBBGDL